<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2022-3-110-114</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1307</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Диацереин в терапии хронической скелетно-мышечной боли</article-title><trans-title-group xml:lang="en"><trans-title>Diacerein in the treatment of chronic musculoskeletal pain</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5103-5447</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полищук</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Polishchuk</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Юрьевна Полищук</p><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>Elena Yurievna Polishchuk</p><p>34A, Kashirskoe shosse, Moscow 115522</p></bio><email xlink:type="simple">dr.pogozheva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1391-0711</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каратеев</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Karateev</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>20</day><month>06</month><year>2022</year></pub-date><volume>16</volume><issue>3</issue><fpage>110</fpage><lpage>114</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Полищук Е.Ю., Каратеев А.Е., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Полищук Е.Ю., Каратеев А.Е.</copyright-holder><copyright-holder xml:lang="en">Polishchuk E.Y., Karateev A.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1307">https://mrj.ima-press.net/mrj/article/view/1307</self-uri><abstract><p>Хроническая скелетно-мышечная боль (СМБ) – наиболее тягостное проявление ревматических заболеваний, основная причина потери трудоспособности, снижения качества и продолжительности жизни пациентов, что определяет не только высокую медицинскую, но и социальную значимость данной проблемы. Хронический характер боли вынуждает пациентов с СМБ длительно использовать анальгетическую терапию. При этом средством «первой линии» для лечения СМБ являются нестероидные противовоспалительные препараты (НПВП). Однако хорошо известно, что применение данной группы препаратов сопряжено со значительными трудностями, в основном из-за часто встречающейся у людей среднего и пожилого возраста коморбидной патологии. В связи с этим продолжаются попытки поиска альтернативных средств для контроля хронической СМБ, обладающих сходной с НПВП обезболивающей и противовоспалительной активностью, но лишенных их побочных эффектов. Некоторые исследователи считают, что таким препаратом может стать диацереин.</p></abstract><trans-abstract xml:lang="en"><p>Chronic musculoskeletal pain (MSP) is the most painful manifestation of rheumatic diseases (RD), the main cause of disability, a decrease in the quality and life expectancy of patients, which determines not only the high medical, but also the social significance of this problem. The chronic nature of the pain forces patients with MSP to use analgesic therapy for a long time. At the same time, non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line treatment for MSP. However, it is well known that the use of this group of drugs is associated with significant difficulties, mainly due to the comorbid pathology that is common in middle-aged and elderly people. In this regard, there are continuing attempts at searching for alternative agents for chronic MSP control, which have analgesic and anti-inflammatory activity similar to NSAIDs, but lack their side effects. Some researchers believe that diacerein can become such drug.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>скелетно-мышечная боль</kwd><kwd>диацереин (Артрокер)</kwd><kwd>эффективность</kwd><kwd>безопасность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>musculoskeletal pain</kwd><kwd>diacerein (Artroker)</kwd><kwd>efficiency</kwd><kwd>safety</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья спонсируется компанией ООО «Микро Лабс Лимитед».</funding-statement><funding-statement xml:lang="en">This article has been supported by Micro Labs Limited.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Яхно НН, Каратеев АЕ и др. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016;54(3):247-65.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of treatment for musculoskeletal pain: Interdisciplinary consensus. Nauchno-Prakticheskaya Revmatologiya. 2016; 54(3):247-65. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2020. 448 с.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2020. 448 p.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bruyere O, Honvo G, Veronese N. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec;49(3): 337-50. doi: 10.1016/j.semarthrit.2019.04.008. Epub 2019 Apr 30.</mixed-citation><mixed-citation xml:lang="en">Bruyere O, Honvo G, Veronese N. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec;49(3): 337-50. doi: 10.1016/j.semarthrit.2019.04.008. Epub 2019 Apr 30.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Pelletier JP, Raynauld JP, Dorais M, et al. An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. Rheumatology (Oxford). 2020 Dec 1; 59(12):3858-68. doi: 10.1093/rheumatology/keaa072.</mixed-citation><mixed-citation xml:lang="en">Pelletier JP, Raynauld JP, Dorais M, et al. An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. Rheumatology (Oxford). 2020 Dec 1; 59(12):3858-68. doi: 10.1093/rheumatology/keaa072.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Franchi-Micheli S, Lavacchi L, Friedmann CA, Zilletti L. The influence of rhein on the biosynthesis of prostaglandin-like substances in vitro. J Pharm Pharmacol. 1983 Apr;35(4):262-4. doi: 10.1111/j.2042-7158.1983.tb02929.x.</mixed-citation><mixed-citation xml:lang="en">Franchi-Micheli S, Lavacchi L, Friedmann CA, Zilletti L. The influence of rhein on the biosynthesis of prostaglandin-like substances in vitro. J Pharm Pharmacol. 1983 Apr;35(4):262-4. doi: 10.1111/j.2042-7158.1983.tb02929.x.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Almezgagi M, Zhang Y, Hezam K, et al. Diacerein: Recent insight into pharmacological activities and molecular pathways. Biomed Pharmacother. 2020 Nov;131:110594. doi: 10.1016/j.biopha.2020.110594. Epub 2020 Aug 25.</mixed-citation><mixed-citation xml:lang="en">Almezgagi M, Zhang Y, Hezam K, et al. Diacerein: Recent insight into pharmacological activities and molecular pathways. Biomed Pharmacother. 2020 Nov;131:110594. doi: 10.1016/j.biopha.2020.110594. Epub 2020 Aug 25.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Pelletier J, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000 Oct;43(10):2339-48. doi: 10.1002/1529-0131(200010)43:10&lt;2339::AID-ANR23&gt;3.0.CO;2-P.</mixed-citation><mixed-citation xml:lang="en">Pelletier J, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000 Oct;43(10):2339-48. doi: 10.1002/1529-0131(200010)43:10&lt;2339::AID-ANR23&gt;3.0.CO;2-P.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Pavelka K, Trc T, Karpas K, et al. The Efficacy and Safety of Diacerein in the Treatment of Painful Osteoarthritis of the Knee. Arthritis Rheum. 2007 Dec;56(12):4055-64. doi: 10.1002/art.23056.</mixed-citation><mixed-citation xml:lang="en">Pavelka K, Trc T, Karpas K, et al. The Efficacy and Safety of Diacerein in the Treatment of Painful Osteoarthritis of the Knee. Arthritis Rheum. 2007 Dec;56(12):4055-64. doi: 10.1002/art.23056.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moзa Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014 Feb 10;2:CD005117. doi: 10.1002/14651858.CD005117.pub3.</mixed-citation><mixed-citation xml:lang="en">Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moзa Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014 Feb 10;2:CD005117. doi: 10.1002/14651858.CD005117.pub3.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Louthrenoo W, Nilganuwong S, Aksaranugraha S, et al. The efficacy, safety and carry- over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study. Osteoarthritis Cartilage. 2007 Jun;15(6): 605-14. doi: 10.1016/j.joca.2007.02.021. Epub 2007 Apr 19.</mixed-citation><mixed-citation xml:lang="en">Louthrenoo W, Nilganuwong S, Aksaranugraha S, et al. The efficacy, safety and carry- over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study. Osteoarthritis Cartilage. 2007 Jun;15(6): 605-14. doi: 10.1016/j.joca.2007.02.021. Epub 2007 Apr 19.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng W, Tang F, Li J, et al. Evaluation of efficacy and safety of diacerein in knee osteoarthritis in Chinese patients. Chin Med Sci J. 2006 Jun;21(2):75-80.</mixed-citation><mixed-citation xml:lang="en">Zheng W, Tang F, Li J, et al. Evaluation of efficacy and safety of diacerein in knee osteoarthritis in Chinese patients. Chin Med Sci J. 2006 Jun;21(2):75-80.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Assessment report for diacerein containing medicinal products. 28 August 2014 EMA/ 527347/2014. https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-prac-assessment-report_en.pdf</mixed-citation><mixed-citation xml:lang="en">Assessment report for diacerein containing medicinal products. 28 August 2014 EMA/ 527347/2014. https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-prac-assessment-report_en.pdf</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Лапшина CA, Мясоутова ЛИ, Салихов ИГ, Васильев АГ. Оценка эффективности и безопасности препарата Артрокер (диацереин) у пациентов с остеоартрозом коленного сустава. Современное искусство медицины. 2011;(2):29-33.</mixed-citation><mixed-citation xml:lang="en">Lapshina SA, Myasoutova LI, Salikhov IG, Vasil'ev AG. Evaluation of the efficacy and safety of the drug Arthroker (diacerein) in patients with osteoarthritis of the knee joint. Sovremennoe iskusstvo meditsiny. 2011;(2): 29-33. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Заигрова НК. Оценка эффективности препарата Артрокер® при остеоартрозе коленных суставов. Современная ревматология. 2013;7(4):23-5.</mixed-citation><mixed-citation xml:lang="en">Zaigrova NK. Evaluation of the efficacy of Arthrocare® for knee osteoarthrosis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(4):23-5. (In Russ.). doi: 10.14412/1996-7012-2013-2434.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Шарапова ЕП, Кашеварова НГ, Зайцева ЕМ и др. Оценка эффективности и безопасности диацереина у пациентов с остеоартрозом тазобедренных суставов. Медицинский совет. 2017;(1S):84-90.</mixed-citation><mixed-citation xml:lang="en">Sharapova EP, Kashevarova NG, Zaitseva EM, et al. Evaluation of efficacy and safety of diacerein in patients with osteoarthritis of the hip joints. Meditsinskii sovet. 2017;(1S):84-90. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Евстратова ЕФ, Васильева ЛВ, Толстых ЕМ, Золотарева МА. Динамические изменения клинических и лабораторных симптомов тяжести остеоартрита, как маркеры рационального лечения в условиях амбулаторного приема. Актуальные научные исследования в современном мире. 2019;(9-2):24-9.</mixed-citation><mixed-citation xml:lang="en">Evstratova EF, Vasil'eva LV, Tolstykh EM, Zolotareva MA. Dynamic changes in clinical and laboratory symptoms of osteoarthritis severity as markers of rational treatment in outpatient settings. Aktual'nye nauchnye issledovaniya v sovremennom mire. 2019;(9-2): 24-9. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Стародубцева ИА, Васильева ЛВ, Никитин АВ. Терапевтический подход с использованием препарата артрокер в лечении вторичного остеоартроза у больных ревматоидным артритом. Клиническая геронтология. 2013;(5):49-51.</mixed-citation><mixed-citation xml:lang="en">Starodubtseva IA, Vasil'eva LV, Nikitin AV. Therapeutic approach using the drug arthroker in the treatment of secondary osteoarthritis in patients with rheumatoid arthritis. Klinicheskaya gerontologiya. 2013;(5):49-51. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Успенский ЮП, Иванов СВ, Фоминых ЮА, Рахов ДА. Влияние диацереина на клиническое течение остеоартрита и эндотелиальную дисфункцию у пациентов с артериальной гипертензией. Лечащий врач. 2018;(4):40-5.</mixed-citation><mixed-citation xml:lang="en">Uspenskii YuP, Ivanov SV, Fominykh YuA, Rakhov DA. The effect of diacerein on the clinical course of osteoarthritis and endothelial dysfunction in patients with arterial hypertension. Lechashchii vrach. 2018;(4):40-5. (In Russ.).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
